United States · Markets & Finance · The Motley Fool

Should You Invest in This Dividend King on the Dip?

Published by The Motley Fool · United States 7 h ago

Icotyde's approval was significant for Johnson & Johnson because it introduced the first oral IL-23 receptor antagonist (a drug that blocks a receptor involved in inflammation),…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

CNBC

AI stocks plunge. Inflation heats up. Where we're still finding opportunities

Seeking Alpha

Earnings Scoreboard: 83% of S&P 500 early reporters beat EPS estimates as Y/Y profit growth hits 23 firms

Business Insider

I'm a Colorado local. If I had one day to show you my state, I'd skip Denver and take you to a city just west of it.

TechCrunch

Ember’s new temperature-controlled mug makes my nightly tea ritual even better

NYT Business

The Reporter Who Exposed Elizabeth Holmes on Nathan Fielder’s Documentary

Quartz